Intelgenx Technologs (IGXT) 0.6190 $IGXT
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
IntelGenx to Present at the 8th Annual OneMedForum
GlobeNewswire - Mon Jan 05, 7:25AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the 8 Annual OneMedForum to be held Monday, January 12, 2015 at the San Francisco Marriott Marquis. IntelGenx' presentation will take place January 12, 2015 at 10:40 A.M. Pacific Time.
IGX.VN: 0.750 (unch)
IntelGenx Grants Stock Options
GlobeNewswire - Mon Dec 08, 1:54PM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company" (TSX-V:IGX) (OTC.QX:IGXT) announced today that the Company's board of directors granted options to acquire 175,000 common shares under the 2006 Stock Option Plan as amended. Of the total stock options granted, 25,000 were granted to each of the following non-employee directors Bernard Boudreau, Ian Troup and Bernd Melchers, 25,000 were granted to each of Horst G. Zerbe, the Chief Executive Officer and Paul A. Simmons, the Chief Financial Officer. Another 25,000 stock options were granted to each of two of the companies employees.
IGX.VN: 0.750 (unch)
IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
GlobeNewswire - Tue Dec 02, 6:32AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont" has exercised its right to extend the license for the exclusive marketing of Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.750 (unch)
German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST
RDHL: 12.69 (+0.04)
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM" has validated the European Marketing Authorization Application submitted for RIZAPORT(TM) and initiated its formal review of the application on November 25, 2014
RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Wed Nov 26, 7:41AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.750 (unch)
IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Tue Nov 25, 7:08AM CST
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets.
IGX.VN: 0.750 (unch)
Stocks to watch ahead of the "Best of the Uncovereds" conference
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:45AM CST
ACET: 20.00 (+0.27), ACU: 18.70 (unch), BONE: 3.09 (+0.09), MNTX: 11.54 (+0.10), TREC: 14.54 (+0.20), INTL: 23.43 (+0.46), HPJ: 5.71 (+0.16), SPA: 22.31 (-0.02), AXPW: 0.39 (-0.04), DXPE: 46.57 (+1.42), LODE: 0.84 (unch), LABL: 63.28 (+0.85), NEWT: 15.13 (-0.12), SA: 8.08 (+0.04), PSEC: 8.67 (+0.07)
IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
GlobeNewswire - Tue Nov 18, 7:40AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time.
IGX.VN: 0.750 (unch)
IntelGenx reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:19AM CST
IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update
GlobeNewswire - Wed Nov 12, 7:02AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced financial results for the three and nine months ended September 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated.
IGX.VN: 0.750 (unch)
Small Cap Traders Delivers Brief Report: IntelGenx Technologies Corporation Targeting Better Outcomes
PR Newswire - Thu Nov 06, 6:00AM CST
Brief Analyst Report by Small Cap Traders. IntelGenx Technologies Corporation (OTCBB: IGXT) - According to a January 2014 report by BCCResearch, global revenues for advanced drug delivery systems in 2013 were an estimated $151.3 billion. Revenues for advanced drug delivery systems are estimated to grow by compound annual growth rate (CAGR) of 2.8% through 2018, reaching $173.8 billion. These targeted drug delivery systems are used to increase the concentration of medications in some parts of the human body relative to other parts. This reduces the frequency of drug dosages required by the patient, results in a more uniform effect from the drug, and lowers drug side-effects. One company involved in this industry is IntelGenx Technologies Corporation.
IntelGenx Announces Successful Clinical Study for Schizophrenia
GlobeNewswire - Mon Nov 03, 7:37AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company" today announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. INT0036 is indicated for the treatment of schizophrenia and utilizes the Company's proprietary VersaFilm(TM) technology.
IGX.VN: 0.750 (unch)
This Small Cap Is Poised To Tap Multi-Billion Dollar Migraine Treatment Market
Tedra DeSue - at Seeking Alpha - Thu Oct 16, 8:14AM CDT
RDHL: 12.69 (+0.04)
IntelGenx Founder Returns as President and CEO
GlobeNewswire - Thu Oct 02, 7:02AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" today announced that its board of directors unanimously decided to appoint the company's founder, Dr. Horst G. Zerbe, as President and Chief Executive Officer. Dr. Zerbe led the company in the same roles from April 2006 to December 2013 and also has been serving as interim President and CEO since July 2014.
IGX.VN: 0.750 (unch)
RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, that they have submitted a Marketing Authorization Application ("MAA" to the German Federal Institute for Drugs and Medical Devices ("BfArM" seeking European marketing approval of RHB-103, an oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT. The brand name RIZAPORT for RHB-103 was also conditionally approved by the U.S. Food and Drug Administration ("FDA" as part of the New Drug Application ("NDA" review process in the U.S., subject to a Complete Response Letter ("CRL" received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that they have submitted a Marketing Authorization Application ("MAA" to the German Federal Institute for Drugs and Medical Devices ("BfArM" seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT(R). The brand name RIZAPORT(R) was also conditionally approved by the U.S. Food and Drug Administration ("FDA" as part of the New Drug Application ("NDA" review process in the U.S., subject to a Complete Response Letter ("CRL" received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
IntelGenx to Present at the 8th Annual OneMedForum
GlobeNewswire - Mon Jan 05, 7:25AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the 8 Annual OneMedForum to be held Monday, January 12, 2015 at the San Francisco Marriott Marquis. IntelGenx' presentation will take place January 12, 2015 at 10:40 A.M. Pacific Time. IGX.VN: 0.750 (unch)
IntelGenx Grants Stock Options
GlobeNewswire - Mon Dec 08, 1:54PM CST
IntelGenx Technologies Corp. ("IntelGenx", or the "Company"
(TSX-V:IGX) (OTC.QX:IGXT) announced today that the Company's board of directors granted options to acquire 175,000 common shares under the 2006 Stock Option Plan as amended. Of the total stock options granted, 25,000 were granted to each of the following non-employee directors Bernard Boudreau, Ian Troup and Bernd Melchers, 25,000 were granted to each of Horst G. Zerbe, the Chief Executive Officer and Paul A. Simmons, the Chief Financial Officer. Another 25,000 stock options were granted to each of two of the companies employees. IGX.VN: 0.750 (unch)
IntelGenx Grants Extension of Marketing Exclusivity in the U.S. to Edgemont of Forfivo XL(R)
GlobeNewswire - Tue Dec 02, 6:32AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont" has exercised its right to extend the license for the exclusive marketing of Forfivo XL(R) 450 mg tablets. IGX.VN: 0.750 (unch)
German regulator starts review of Rizaport MAA
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:43AM CST
RDHL: 12.69 (+0.04)
IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:03AM CST
-- The German Federal Institute for Drugs and Medical Devices ("BfArM"
has validated the European Marketing Authorization Application submitted for RIZAPORT(TM) and initiated its formal review of the application on November 25, 2014 RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines
GlobeNewswire - Mon Dec 01, 7:00AM CST
-- The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT (RHB-103) and initiated its formal review of the application on November 25, 2014
RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Wed Nov 26, 7:41AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets. IGX.VN: 0.750 (unch)
IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)
GlobeNewswire - Tue Nov 25, 7:08AM CST
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that it has settled its Paragraph IV litigation with Wockhardt Bio AG related to IntelGenx' Forfivo XL(R) 450 mg tablets. IGX.VN: 0.750 (unch)
Stocks to watch ahead of the "Best of the Uncovereds" conference
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:45AM CST
ACET: 20.00 (+0.27), ACU: 18.70 (unch), BONE: 3.09 (+0.09), MNTX: 11.54 (+0.10), TREC: 14.54 (+0.20), INTL: 23.43 (+0.46), HPJ: 5.71 (+0.16), SPA: 22.31 (-0.02), AXPW: 0.39 (-0.04), DXPE: 46.57 (+1.42), LODE: 0.84 (unch), LABL: 63.28 (+0.85), NEWT: 15.13 (-0.12), SA: 8.08 (+0.04), PSEC: 8.67 (+0.07)
IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference
GlobeNewswire - Tue Nov 18, 7:40AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time. IGX.VN: 0.750 (unch)
IntelGenx reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:19AM CST
IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update
GlobeNewswire - Wed Nov 12, 7:02AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced financial results for the three and nine months ended September 30, 2014 and provided an update on corporate developments. All amounts are in U.S. Dollars, unless otherwise stated. IGX.VN: 0.750 (unch)
Small Cap Traders Delivers Brief Report: IntelGenx Technologies Corporation Targeting Better Outcomes
PR Newswire - Thu Nov 06, 6:00AM CST
Brief Analyst Report by Small Cap Traders. IntelGenx Technologies Corporation (OTCBB: IGXT) - According to a January 2014 report by BCCResearch, global revenues for advanced drug delivery systems in 2013 were an estimated $151.3 billion. Revenues for advanced drug delivery systems are estimated to grow by compound annual growth rate (CAGR) of 2.8% through 2018, reaching $173.8 billion. These targeted drug delivery systems are used to increase the concentration of medications in some parts of the human body relative to other parts. This reduces the frequency of drug dosages required by the patient, results in a more uniform effect from the drug, and lowers drug side-effects. One company involved in this industry is IntelGenx Technologies Corporation.
IntelGenx Announces Successful Clinical Study for Schizophrenia
GlobeNewswire - Mon Nov 03, 7:37AM CST
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company"
today announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. INT0036 is indicated for the treatment of schizophrenia and utilizes the Company's proprietary VersaFilm(TM) technology. IGX.VN: 0.750 (unch)
This Small Cap Is Poised To Tap Multi-Billion Dollar Migraine Treatment Market
Tedra DeSue - at Seeking Alpha - Thu Oct 16, 8:14AM CDT
RDHL: 12.69 (+0.04)
IntelGenx Founder Returns as President and CEO
GlobeNewswire - Thu Oct 02, 7:02AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
today announced that its board of directors unanimously decided to appoint the company's founder, Dr. Horst G. Zerbe, as President and Chief Executive Officer. Dr. Zerbe led the company in the same roles from April 2006 to December 2013 and also has been serving as interim President and CEO since July 2014. IGX.VN: 0.750 (unch)
RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced, together with IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" , a Canadian drug delivery company focused on oral drug delivery, that they have submitted a Marketing Authorization Application ("MAA" to the German Federal Institute for Drugs and Medical Devices ("BfArM" seeking European marketing approval of RHB-103, an oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT. The brand name RIZAPORT for RHB-103 was also conditionally approved by the U.S. Food and Drug Administration ("FDA" as part of the New Drug Application ("NDA" review process in the U.S., subject to a Complete Response Letter ("CRL" received from the FDA in February 2014 and currently under discussions with the FDA. RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"
, a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that they have submitted a Marketing Authorization Application ("MAA" to the German Federal Institute for Drugs and Medical Devices ("BfArM" seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT(R). The brand name RIZAPORT(R) was also conditionally approved by the U.S. Food and Drug Administration ("FDA" as part of the New Drug Application ("NDA" review process in the U.S., subject to a Complete Response Letter ("CRL" received from the FDA in February 2014 and currently under discussions with the FDA. RDHL: 12.69 (+0.04), IGX.VN: 0.750 (unch)
